Integra LifeSciences Holdings Corporation announced that its board of directors has appointed Mojdeh Poul as the new chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain CEO until January 6, 2025.

Stuart Essig will remain executive chairman of Integra for a limited period of time before returning to his prior role as non-executive chairman. Most recently, Ms. Poul was the executive vice president and group president for 3M?s $8.5B Global Healthcare Business, comprised of four business units, including advanced wound care. In this role, she had global accountability for all functions ?

R&D, manufacturing and commercial operations, quality, and regulatory. Ms. Poul and her team led the transformation of the healthcare portfolio through a number of strategic acquisitions and divestitures, as well as organic product and business model innovation. Before joining 3M, Ms. Poul held global business leadership positions of increasing responsibility at Medtronic and Boston Scientific.

In these roles, she accelerated penetration of neuromodulation and emerging cardiovascular technologies and therapies through the deployment of multifaceted market development strategies. Ms. Poul currently serves on the board of directors and is a member of the audit committee at Align Technology. She is also a board director and member of the audit committee at iRhythm Technologies, as well as a board director and member of the audit, and the compensation and talent development committees at Stanley Black and Decker.

Ms. Poul received her bachelor?s and master?s degrees in mechanical engineering from the University of Louisville. She also holds an MBA from the University of North Carolina at Chapel Hill.